$0.57
10.56% yesterday
Nasdaq, Apr 07, 10:08 pm CET
ISIN
US81750R1023
Symbol
MCRB
Sector
Industry

Seres Therapeutics Inc Target price 2025 - Analyst rating & recommendation

Seres Therapeutics Inc Classifications & Recommendation:

Buy
57%
Hold
14%
Sell
29%

Seres Therapeutics Inc Price Target

Target Price $3.25
Price $0.57
Potential
Number of Estimates 4
4 Analysts have issued a price target Seres Therapeutics Inc 2026 . The average Seres Therapeutics Inc target price is $3.25. This is higher than the current stock price. The highest price target is
$10.00 1,647.03%
register free of charge
, the lowest is .
A rating was issued by 7 analysts: 4 Analysts recommend Seres Therapeutics Inc to buy, 1 to hold and 2 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Seres Therapeutics Inc stock has an average upside potential 2026 of . Most analysts recommend the Seres Therapeutics Inc stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -0.94 -0.16
5.62% 82.98%
P/E negative
EV/Sales 4.86

6 Analysts have issued a Seres Therapeutics Inc forecast for earnings per share. The average Seres Therapeutics Inc EPS is

$-0.16
Unlock
. This is
83.33% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$0.44 145.83%
Unlock
, the lowest is
$-0.57 40.63%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-0.94 5.62%
2025
$-0.16 82.98%
Unlock
2026
$-0.24 50.00%
Unlock
2027
$0.05 120.83%
Unlock
2028
$-0.50 1,100.00%
Unlock
2029
$-0.50 0.00%
Unlock

P/E ratio

Current -0.60 29.41%
2025
-3.59 498.33%
Unlock
2026
-2.37 33.98%
Unlock
2027
12.32 619.83%
Unlock
2028
-1.14 109.25%
Unlock
2029
-1.14 0.00%
Unlock

Current Seres Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Chardan Capital
Locked
Locked
Locked Mar 20 2025
Goldman Sachs
Locked
Locked
Locked Mar 14 2025
Canaccord Genuity
Locked
Locked
Locked Nov 14 2024
Chardan Capital
Locked
Locked
Locked Nov 13 2024
JP Morgan
Locked
Locked
Locked Oct 24 2024
Canaccord Genuity
Locked
Locked
Locked Sep 13 2024
Analyst Rating Date
Locked
Chardan Capital:
Locked
Locked
Mar 20 2025
Locked
Goldman Sachs:
Locked
Locked
Mar 14 2025
Locked
Canaccord Genuity:
Locked
Locked
Nov 14 2024
Locked
Chardan Capital:
Locked
Locked
Nov 13 2024
Locked
JP Morgan:
Locked
Locked
Oct 24 2024
Locked
Canaccord Genuity:
Locked
Locked
Sep 13 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today